A detailed history of Sei Investments CO transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Sei Investments CO holds 9,799 shares of MDGL stock, worth $2.04 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,799
Previous 10,455 6.27%
Holding current value
$2.04 Million
Previous $2.79 Million 1.65%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$193.33 - $291.99 $126,824 - $191,545
-656 Reduced 6.27%
9,799 $2.75 Million
Q1 2024

May 07, 2024

SELL
$171.37 - $283.23 $79,344 - $131,135
-463 Reduced 4.24%
10,455 $2.79 Million
Q4 2023

Feb 14, 2024

BUY
$120.4 - $237.13 $99,932 - $196,817
830 Added 8.23%
10,918 $2.53 Million
Q3 2023

Nov 14, 2023

SELL
$146.04 - $225.78 $463,823 - $717,077
-3,176 Reduced 23.94%
10,088 $1.47 Million
Q2 2023

Aug 11, 2023

BUY
$203.88 - $312.0 $1.06 Million - $1.63 Million
5,221 Added 64.91%
13,264 $3.06 Million
Q1 2023

May 12, 2023

BUY
$231.06 - $307.08 $642,115 - $853,375
2,779 Added 52.79%
8,043 $1.95 Million
Q4 2022

Feb 10, 2023

BUY
$58.39 - $296.54 $307,364 - $1.56 Million
5,264 New
5,264 $1.53 Million
Q2 2022

Aug 15, 2022

SELL
$58.04 - $100.2 $163,846 - $282,864
-2,823 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$55.89 - $101.89 $4,471 - $8,151
80 Added 2.92%
2,823 $277,000
Q4 2021

Feb 14, 2022

SELL
$72.34 - $95.09 $16,927 - $22,251
-234 Reduced 7.86%
2,743 $232,000
Q2 2021

Aug 06, 2021

BUY
$97.2 - $137.59 $289,364 - $409,605
2,977 New
2,977 $290,000
Q1 2019

May 15, 2019

SELL
$103.48 - $143.84 $48,118 - $66,885
-465 Closed
0 $0
Q3 2018

Nov 08, 2018

SELL
$207.3 - $300.31 $1.1 Million - $1.59 Million
-5,291 Reduced 91.92%
465 $100,000
Q2 2018

Aug 03, 2018

BUY
$101.55 - $313.9 $584,521 - $1.81 Million
5,756 New
5,756 $1.61 Million

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $3.56B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Sei Investments CO Portfolio

Follow Sei Investments CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

News

Stay updated on Sei Investments CO with notifications on news.